SMALL  ||| S:0 E:6 ||| NNP
CELL  ||| S:6 E:11 ||| NNP
CARCINOMA  ||| S:11 E:21 ||| NNP
OF  ||| S:21 E:24 ||| IN
THE  ||| S:24 E:28 ||| DT
PROSTATE ||| S:28 E:36 ||| NNP
:  ||| S:36 E:38 ||| :
A  ||| S:38 E:40 ||| DT
CASE  ||| S:40 E:45 ||| NN
REPORT  ||| S:45 E:52 ||| NN
OF  ||| S:52 E:55 ||| IN
RELATIVE  ||| S:55 E:64 ||| NNP
LONG-TERM  ||| S:64 E:74 ||| NNP
SURVIVAL  ||| S:74 E:83 ||| NNP
Small  ||| S:83 E:89 ||| NNP
cell  ||| S:89 E:94 ||| NN
carcinoma  ||| S:94 E:104 ||| NN
of  ||| S:104 E:107 ||| IN
the  ||| S:107 E:111 ||| DT
prostate  ||| S:111 E:120 ||| NN
( ||| S:120 E:121 ||| -LRB-
SCCP ||| S:121 E:125 ||| NNP
)  ||| S:125 E:127 ||| -RRB-
is  ||| S:127 E:130 ||| VBZ
rare ||| S:130 E:134 ||| JJ
,  ||| S:134 E:136 ||| ,
and  ||| S:136 E:140 ||| CC
no  ||| S:140 E:143 ||| DT
standard  ||| S:143 E:152 ||| JJ
treatment  ||| S:152 E:162 ||| NN
regimen  ||| S:162 E:170 ||| NN
has  ||| S:170 E:174 ||| VBZ
yet  ||| S:174 E:178 ||| RB
been  ||| S:178 E:183 ||| VBN
established ||| S:183 E:194 ||| VBN
.  ||| S:194 E:196 ||| .
The  ||| S:196 E:200 ||| DT
overall  ||| S:200 E:208 ||| JJ
prognosis  ||| S:208 E:218 ||| NN
remains  ||| S:218 E:226 ||| VBZ
poor ||| S:226 E:230 ||| JJ
.  ||| S:230 E:232 ||| .
We  ||| S:232 E:235 ||| PRP
experienced  ||| S:235 E:247 ||| VBD
a  ||| S:247 E:249 ||| DT
case  ||| S:249 E:254 ||| NN
who  ||| S:254 E:258 ||| WP
obtained  ||| S:258 E:267 ||| VBD
relative  ||| S:267 E:276 ||| JJ
long-term  ||| S:276 E:286 ||| JJ
survival  ||| S:286 E:295 ||| NN
with  ||| S:295 E:300 ||| IN
two  ||| S:300 E:304 ||| CD
types  ||| S:304 E:310 ||| NNS
of  ||| S:310 E:313 ||| IN
chemotherapy  ||| S:313 E:326 ||| JJ
treatments ||| S:326 E:336 ||| NNS
.  ||| S:336 E:338 ||| .
A  ||| S:338 E:340 ||| DT
69-year-old  ||| S:340 E:352 ||| JJ
man  ||| S:352 E:356 ||| NN
underwent  ||| S:356 E:366 ||| VBD
combined  ||| S:366 E:375 ||| VBN
androgen  ||| S:375 E:384 ||| JJ
blockade  ||| S:384 E:393 ||| NN
( ||| S:393 E:394 ||| -LRB-
CAB ||| S:394 E:397 ||| NNP
)  ||| S:397 E:399 ||| -RRB-
with  ||| S:399 E:404 ||| IN
a  ||| S:404 E:406 ||| DT
diagnosis  ||| S:406 E:416 ||| NN
of  ||| S:416 E:419 ||| IN
prostate  ||| S:419 E:428 ||| JJ
adenocarcinoma  ||| S:428 E:443 ||| NNS
( ||| S:443 E:444 ||| -LRB-
Gleason  ||| S:444 E:452 ||| NNP
score  ||| S:452 E:458 ||| NN
=  ||| S:458 E:460 ||| SYM
5  ||| S:460 E:462 ||| CD
+  ||| S:462 E:464 ||| CD
3 ||| S:464 E:465 ||| CD
)  ||| S:465 E:467 ||| -RRB-
that  ||| S:467 E:472 ||| WDT
was  ||| S:472 E:476 ||| VBD
staged  ||| S:476 E:483 ||| VBN
T3bN1M1b  ||| S:483 E:492 ||| NNP
( ||| S:492 E:493 ||| -LRB-
initial  ||| S:493 E:501 ||| JJ
PSA  ||| S:501 E:505 ||| NNP
=  ||| S:505 E:507 ||| SYM
352  ||| S:507 E:511 ||| CD
ng ||| S:511 E:513 ||| CD
/ ||| S:513 E:514 ||| CD
ml ||| S:514 E:516 ||| CD
) ||| S:516 E:517 ||| -RRB-
.  ||| S:517 E:519 ||| .
Twenty-five  ||| S:519 E:531 ||| CD
months  ||| S:531 E:538 ||| NNS
after  ||| S:538 E:544 ||| IN
hormonal  ||| S:544 E:553 ||| JJ
therapy ||| S:553 E:560 ||| NN
,  ||| S:560 E:562 ||| ,
the  ||| S:562 E:566 ||| DT
level  ||| S:566 E:572 ||| NN
of  ||| S:572 E:575 ||| IN
serum  ||| S:575 E:581 ||| JJ
PSA  ||| S:581 E:585 ||| NNP
had  ||| S:585 E:589 ||| VBD
elapsed  ||| S:589 E:597 ||| RB
remain  ||| S:597 E:604 ||| VB
low ||| S:604 E:607 ||| JJ
,  ||| S:607 E:609 ||| ,
however ||| S:609 E:616 ||| RB
,  ||| S:616 E:618 ||| ,
FDG-PET ||| S:618 E:625 ||| NNP
/ ||| S:625 E:626 ||| NNP
CT  ||| S:626 E:629 ||| NNP
revealed  ||| S:629 E:638 ||| VBD
high  ||| S:638 E:643 ||| JJ
value  ||| S:643 E:649 ||| NN
at  ||| S:649 E:652 ||| IN
the  ||| S:652 E:656 ||| DT
lymph  ||| S:656 E:662 ||| JJ
node  ||| S:662 E:667 ||| NN
of  ||| S:667 E:670 ||| IN
para-aortic  ||| S:670 E:682 ||| JJ
and  ||| S:682 E:686 ||| CC
pelvic  ||| S:686 E:693 ||| JJ
lesion ||| S:693 E:699 ||| NN
.  ||| S:699 E:701 ||| .
The  ||| S:701 E:705 ||| DT
levels  ||| S:705 E:712 ||| NNS
of  ||| S:712 E:715 ||| IN
serum  ||| S:715 E:721 ||| JJ
NSE  ||| S:721 E:725 ||| NNP
and  ||| S:725 E:729 ||| CC
Pro-GRP  ||| S:729 E:737 ||| JJ
elevated ||| S:737 E:745 ||| NN
,  ||| S:745 E:747 ||| ,
and  ||| S:747 E:751 ||| CC
a  ||| S:751 E:753 ||| DT
prostate  ||| S:753 E:762 ||| JJ
re-biopsy  ||| S:762 E:772 ||| NN
revealed  ||| S:772 E:781 ||| VBD
a  ||| S:781 E:783 ||| DT
small  ||| S:783 E:789 ||| JJ
cell  ||| S:789 E:794 ||| NN
carcinoma ||| S:794 E:803 ||| NN
.  ||| S:803 E:805 ||| .
Therefore ||| S:805 E:814 ||| RB
,  ||| S:814 E:816 ||| ,
he  ||| S:816 E:819 ||| PRP
was  ||| S:819 E:823 ||| VBD
treated  ||| S:823 E:831 ||| VBN
with  ||| S:831 E:836 ||| IN
12-cycles  ||| S:836 E:846 ||| CD
of  ||| S:846 E:849 ||| IN
combination  ||| S:849 E:861 ||| NN
chemotherapy  ||| S:861 E:874 ||| VBZ
consisting  ||| S:874 E:885 ||| VBG
of  ||| S:885 E:888 ||| IN
etoposide  ||| S:888 E:898 ||| NN
and  ||| S:898 E:902 ||| CC
carboplatin ||| S:902 E:913 ||| NN
.  ||| S:913 E:915 ||| .
Then ||| S:915 E:919 ||| RB
,  ||| S:919 E:921 ||| ,
disease  ||| S:921 E:929 ||| NN
has  ||| S:929 E:933 ||| VBZ
progressed ||| S:933 E:943 ||| VBN
,  ||| S:943 E:945 ||| ,
so  ||| S:945 E:948 ||| RB
he  ||| S:948 E:951 ||| PRP
was  ||| S:951 E:955 ||| VBD
changed  ||| S:955 E:963 ||| VBN
to  ||| S:963 E:966 ||| TO
second  ||| S:966 E:973 ||| JJ
line  ||| S:973 E:978 ||| NN
chemotherapy  ||| S:978 E:991 ||| NN
with  ||| S:991 E:996 ||| IN
amrubicin ||| S:996 E:1005 ||| NN
.  ||| S:1005 E:1007 ||| .
He  ||| S:1007 E:1010 ||| PRP
underwent  ||| S:1010 E:1020 ||| VBD
12-cycles  ||| S:1020 E:1030 ||| CD
chemotherapy  ||| S:1030 E:1043 ||| NN
with  ||| S:1043 E:1048 ||| IN
amrubicin ||| S:1048 E:1057 ||| NN
,  ||| S:1057 E:1059 ||| ,
but  ||| S:1059 E:1063 ||| CC
he  ||| S:1063 E:1066 ||| PRP
died  ||| S:1066 E:1071 ||| VBD
of  ||| S:1071 E:1074 ||| IN
cancer  ||| S:1074 E:1081 ||| NN
39  ||| S:1081 E:1084 ||| CD
months  ||| S:1084 E:1091 ||| NNS
after  ||| S:1091 E:1097 ||| IN
the  ||| S:1097 E:1101 ||| DT
initial  ||| S:1101 E:1109 ||| JJ
treatment  ||| S:1109 E:1119 ||| NN
of  ||| S:1119 E:1122 ||| IN
SCCP ||| S:1122 E:1126 ||| NNP
.  ||| S:1126 E:1128 ||| .
